#VisualAbstract: Capivasertib in Addition to Fulvestrant Improves Progression-Free Survival in ER+ Advanced Breast Cancer
Click to read this study in The Lancet Oncology.
Read MoreAug 16, 2022
Click to read this study in The Lancet Oncology.
Read MoreAug 13, 2022
Click here to read this study in JAMA.
Read MoreAug 11, 2022
1. In this secondary analysis of the DECLARE-TIMI 58 trial, among 17,160 patients, dapagliflozin...
Read MoreAug 11, 2022
Click to read this study in the Journal of Clinical Oncology.
Read MoreAug 11, 2022
1. Eszopiclone and Lemborexant were more efficacious for acute and long-term insomnia compared to...
Read MoreAug 10, 2022
Click to read this study in JAMA Oncology.
Read MoreAug 10, 2022
Click here to read this study in NEJM.
Read MoreAug 5, 2022
1. Fewer patients in the thrombectomy group achieved an MRS score of 0-2 at 90 days compared to...
Read MoreAug 5, 2022
Click to read this study in The Lancet Oncology.
Read MoreAug 5, 2022
Click here to read this study in NEJM.
Read MoreAug 5, 2022
Click to read this study in the Journal of Clinical Oncology.
Read MoreAug 5, 2022
1. No significant differences in treatment success and rate of adverse events were detected in 8...
Read MoreAug 5, 2022
Click to read this study in JAMA.
Read MoreJul 31, 2022
Click to read this study in JAMA.
Read MoreJul 28, 2022
Click to read this study in JAMA.
Read MoreJul 28, 2022
Click to read this study in JAMA.
Read MoreJul 28, 2022
Click to read this study in the Journal of Clinical Oncology.
Read MoreJul 22, 2022
Click to read this study in JAMA
Read MoreJul 21, 2022
Click to read this study in JAMA.
Read MoreJul 21, 2022
Click to read this study in JAMA.
Read More